News
NUWE
0.2570
-1.31%
-0.0034
Weekly Report: what happened at NUWE last week (0408-0412)?
Weekly Report · 4d ago
NUWELLIS ANNOUNCES LAUNCH OF ULTRAFILTRATION THERAPY USING AQUADEX SMARTFLOW® SYSTEM AT HENRY FORD HEALTH
Reuters · 04/09 13:00
Weekly Report: what happened at NUWE last week (0401-0405)?
Weekly Report · 04/08 10:10
Nuwellis Filed U.S. Patent Application #20240108533: VENOUS BLOOD FLOW STIMULATOR FOR EXTRACORPOREAL THERAPY
Benzinga · 04/04 19:53
Weekly Report: what happened at NUWE last week (0325-0329)?
Weekly Report · 04/01 10:09
Weekly Report: what happened at NUWE last week (0318-0322)?
Weekly Report · 03/25 10:11
Weekly Report: what happened at NUWE last week (0311-0315)?
Weekly Report · 03/18 10:10
Nuwellis, Inc. on the Brink: Racing Against Time to Avoid Nasdaq Delisting
TipRanks · 03/13 06:00
Maxim Group Keeps Their Buy Rating on Nuwellis (NUWE)
TipRanks · 03/12 17:45
Weekly Report: what happened at NUWE last week (0304-0308)?
Weekly Report · 03/11 10:08
Nuwellis Announced Results From Two New Clinical Data Analyses From The AVOID-HF Trial Demonstrating Benefits Of Aquadex System For Heart Failure
Benzinga · 03/07 14:10
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
Barchart · 03/07 08:08
Nuwellis Inc reports results for the quarter ended in December - Earnings Summary
Nuwellis Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $1.56 per share. Revenue rose 9.1% to $2.55 million from a year ago. The average analyst rating on the shares is "buy"
Reuters · 03/05 23:28
Nuwellis Q4 2023 GAAP EPS $(2.240) Misses $(1.390) Estimate, Sales $2.600M Beat $2.551M Estimate
Nuwellis reported quarterly sales of $2.600 million. The company missed the analyst consensus estimate by 11.16 percent. Nuwellis also reported quarterly losses of $1.7 million per share and missed the quarterly sales estimate by 61.15 percent.
Benzinga · 03/05 13:01
*Nuwellis 4Q Research and Development Expenses $1.4M >NUWE
Dow Jones · 03/05 13:01
*Nuwellis 4Q Sales $2.55M >NUWE
Dow Jones · 03/05 13:00
Press Release: Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results. Strong Pediatric Sales, Expanding Margins and Increases Number of New Hospital Accounts. Fourth quarter pediatric revenue grew 35% year over year. Company reports highest total quarter of organic revenue in company history. Company is focused on transforming lives of people with fluid overload.
Dow Jones · 03/05 13:00
Press Release: Nuwellis, Inc. Announces Fourth -3-
Net cash used in operations: 17,937 Cash used to pay debts and liabilities. Cash used in investing activities: 1,278 Net cash provided by cash used to repay debt and liabilities: 1,500 The company has a net cash position of $17.2 billion. A total of $16.1 billion is held in cash and cash equivalents.
Dow Jones · 03/05 13:00
Earnings Scheduled For March 5, 2024
Target is estimated to report quarterly earnings at $2.22 per share on revenue of $29.33 billion. Companies reporting before the bell include NIO, Target and Nordstrom. Companies expected to report earnings for their fourth quarter include Vivid Seats, V2X and NIO.
Benzinga · 03/05 10:00
Notable earnings before Tuesday's open
Seeking Alpha · 03/04 15:36
More
Webull provides a variety of real-time NUWE stock news. You can receive the latest news about Nuwellis Inc through multiple platforms. This information may help you make smarter investment decisions.
About NUWE
Nuwellis, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.